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Abstract: Platelet activation contributes to normal haemostasis but also to pathologic conditions
like stroke and cardiac infarction. Signalling by cGMP and cAMP inhibit platelet activation and are
therefore attractive targets for thrombosis prevention. However, extensive cross-talk between the
cGMP and cAMP signalling pathways in multiple tissues complicates the selective targeting of their
activities. We have used mathematical modelling based on experimental data from the literature
to quantify the steady state behaviour of nitric oxide (NO)/cGMP/cAMP signalling in platelets.
The analysis provides an assessment of NO-induced cGMP synthesis and PKG activation as well as
cGMP-mediated cAMP and PKA activation though modulation of phosphodiesterase (PDE2 and
3) activities. Both one- and two-compartment models of platelet cyclic nucleotide signalling are
presented. The models provide new insight for understanding how NO signalling to cGMP and
indirectly cAMP, can inhibit platelet shape-change, the initial step of platelet activation. Only the
two-compartment models could account for the experimental observation that NO-mediated PKA
activation can occur when the bulk platelet cAMP level is unchanged. The models revealed also a
potential for hierarchical interplay between the different platelet phosphodiesterases. Specifically,
the models predict, unexpectedly, a strong effect of pharmacological inhibitors of cGMP-specific PDE5
on the cGMP/cAMP cross-talk. This may explain the successful use of weak PDE5-inhibitors, such as
dipyridamole, in anti-platelet therapy. In conclusion, increased NO signalling or PDE5 inhibition are
attractive ways of increasing cGMP-cAMP cross-talk selectively in platelets.
Keywords: nitric oxide; platelets; cGMP signalling; cAMP signalling; mathematical modelling;
phosphodiesterase; PDE2; PDE3; PDE5
1. Introduction
Platelets play an important role in the haemostatic machinery, by responding rapidly to damage of
the vascular wall. This response is mediated through several signalling pathways acting downstream
of receptors for von Willebrand Factor (vWF), thrombin and collagen. Autocrine stimulatory
factors such as ADP and thromboxane are important for stimulating further adhesion to fibrinogen,
vWF and collagen (through integrin receptors αIIbβ3, α2β1) and for activating circulating platelets.
The self-stimulatory nature of this process necessitates strict negative regulation. This is achieved
mainly through endothelial factors such as prostacyclin (PGI2) and nitric oxide (NO) that activate
cAMP and cGMP signalling pathways [1] (Figure 1). Deficient inhibitory signal communication from
the endothelium is associated with severe vascular disorders such as atherosclerosis and acute ischemic
stroke [2].
NO rapidly stimulates cGMP production in platelets, by binding to the heme moiety of the soluble
guanylyl cyclase (sGC) (EC 4.6.1.2) [1]. Several downstream targets have been characterized for this
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important inhibitory pathway including the cGMP-dependent protein kinase (PKG, EC 2.7.11.12)
and its substrates vasodilator stimulated phosphoprotein (VASP), inositol 1,4,5-trisphophate
receptor-associated cGMP-dependent protein kinase (IRAG) and Ras-related protein (Rap1B) [1,3].
The second messenger cGMP is rapidly degraded by phosphodiesterases (EC 3.1.4.17), in particular the
cGMP-specific phosphodiesterase 5A (PDE5), which is abundantly expressed in platelets [4] (Figure 1).
PDE5 is activated by binding of cGMP to one of its N-terminal GAF (cGMP-specific and -stimulated,
Anabaena adenylate cyclase and Escherichia coli FhlA) domains, which increases both its Vmax activity
and its affinity for cGMP (lowers the Km-value) [5,6]. In addition, PKG can sensitize PDE5 to cGMP by
phosphorylation, leading mainly to increased affinity of cGMP to the activating GAF-domain [7].
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Figure 1. Signalling pathways affecting platelet cyclic nucleotides. An overview of the platelet 
signalling pathways which influence cGMP and cAMP levels are shown; nitric oxide (NO) stimulate 
cGMP production by activating soluble guanylate cyclase (GC). The cGMP signal is degraded by 
phosphodiesterases (PDEs), where PDE5 dominates and PDE2 contributes slightly. The cGMP 
dependent protein kinase is activated by cGMP and executes much of the signalling by 
phosphorylating important target proteins. The cGMP module also mediates cross-talk with the 
cAMP-module through cGMP production that stimulates (PDE2) or inhibits (PDE3) cAMP 
phosphodiesterases. cAMP is produced by adenylate cyclase (AC, EC 4.6.1.1) that is activated by Gαs 
stimulation, elicited by receptor binding of ligands such as prostaglandins (PGI2, PGE1) or adenosine. 
Platelet agonists such as thrombin, ADP and thomboxane (TxA2) will inhibit cAMP signalling, by 
inhibiting AC through inhibitory Gαi, or by increased cAMP degradation through phosphorylation-
mediated activation of PDE3 by AKT/PKB or PKC. 
2. Results 
2.1. The Modelling Approach and Aims 
We have applied a mechanistic modelling approach where ordinary differential equations are 
used to describe experimentally derived mechanistic and kinetic descriptions of the molecular 
components of platelet cGMP and cAMP signalling (Figure 1). This is a common approach and has 
been used in several previous studies on platelets [14,18,19]. The proteins involved in the signalling 
pathways are well described regarding the equilibrium binding affinities and the enzyme kinetic 
constants, although many of the rate constants are less well elucidated. We have therefore mainly 
focused on the steady state behaviour of the model. The modelling was undertaken in part to be able 
to predict the impact of perturbations (normal or pharmacological) on the activity of the cGMP/cAMP 
signalling cascades. The models should quantify contributions to the signalling process, coming from 
different molecular activities and depending on concentrations of key components in platelets. 
Within these frames we further investigated possible mechanisms for compartmentalized signalling, 
relevant to understand NO/cGMP mediated cAMP/PKA activation. Signal compartmentalization has 
been reported experimentally in platelets [20] and we wanted to investigate how different 
compositions of the signalling components would affect the signalling response in a cyclic nucleotide 
signalling compartment. 
Figure 1. Signalling pathways affecting platelet cyclic nucleotides. An overview of the platelet
signalling pathways which influence cGMP and cAMP levels are shown; nitric oxi e (NO) stimulate
cGMP production by activating soluble guanylate cyclase (GC). The cGMP signal is degraded
by phosphodiesterases (PDEs), wher PDE5 dominates and PDE2 contributes slightly. The cGMP
dependent protein kinase is activated by cGMP and executes much of the signalling by phosphorylating
important target proteins. The cGMP mo ule also mediates cross-talk with the cAMP-module through
cGMP production that stimulates (PDE2) or inhibits (PDE3) cAMP phosphodiesterases. cAMP is
produced by adenylate cyclase (AC, EC 4.6.1.1) that is activated by Gαs stimulation, elicited by
receptor binding of ligands such as prostaglandins (PGI2, PGE1) or adenosine. Platelet agonists such
as thrombin, ADP and thomboxane (TxA2) will inhibit cAMP signalling, by inhibiting AC through
inhibitory Gαi, or by increased cAMP degradation through phosphorylation-mediated activation of
PDE3 by AKT/PKB or PKC.
We have previously shown that NO inhibits platel t shape change through activation of
cAMP-dependent protein kinase (PKA, EC 2.7.11.11) [8]. Platelet shape change is a reversible
process that involves reorganization of the cytoskel ton, resulti g in a transition from discoid to
spherical shape with extending pseudopodia that facilitates adhesion to the vessel wall and thrombus
formation. Cross-com unication between cGMP and cAMP has been reported in many tissue and
cell types ([9–12]) and can be inhibitory or stimulatory depending o th components involved.
In platelets [13] the cross-talk is mostly mediated through the cGMP-stimulated cAMP degradation
by phosphodiestera e 2A (PDE2) and cGMP-inhibit d cAMP degradation by phosphodiesterase 3A
(PDE3) (Figure 1). No cross-communication from cAMP to cGMP has been reported in platelets [14],
although PKA can phosphorylate PDE5 on the PKG site (Ser92), but with 10-fold lower efficiency than
PKG [6].
Nitric oxide stimulation of platelets gives zero to very moderate changes in total cAMP levels [15,16].
Furthermore, inhibitors of cyclic nucleotide phosphodiesterase PDE3 are more efficient than PDE2
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inhibitors to inhibit thrombin-induced platelet shape change and secretion, although PDE2 inhibition
gives rise to higher total cAMP levels [8,13]. This suggests that compartmentalized cAMP signalling
may be important for regulating shape change in platelets.
Clearly, the development of unfavourable thrombotic events rely on complex relationships
between platelets themselves and the surrounding mechano-chemical environment. A more
quantitative understanding of platelet behaviour at different conditions would expectedly facilitate
the identification of high-risk situations and the appropriate treatment. Here we investigated the
cross-communication between platelet cGMP/cAMP (cNMP) pathways downstream of NO by
mechanistic modelling. We studied the role of PDE5 in this cross-talk in details, as PDE5 inhibitors
such as dipyridamole, are used in the clinic together with aspirin for the secondary prevention of
stroke [17]. We have previously shown that NO and dipyridamole act synergistically to inhibit platelet
shape change without increasing the cAMP levels [15]. To understand the underlying mechanism for
this observation we performed modelling of platelet cGMP and cAMP signalling in both one- and two
compartments to assess how different degrees of compartmentation of AC and PDEs influence the
signalling cross-talk between cGMP and cAMP. We show that only a two-compartment model can
explain the experimentally observed cyclic nucleotide concentrations.
2. Results
2.1. The Modelling Approach and Aims
We have applied a mechanistic modelling approach where ordinary differential equations are used
to describe experimentally derived mechanistic and kinetic descriptions of the molecular components
of platelet cGMP and cAMP signalling (Figure 1). This is a common approach and has been used
in several previous studies on platelets [14,18,19]. The proteins involved in the signalling pathways
are well described regarding the equilibrium binding affinities and the enzyme kinetic constants,
although many of the rate constants are less well elucidated. We have therefore mainly focused
on the steady state behaviour of the model. The modelling was undertaken in part to be able to
predict the impact of perturbations (normal or pharmacological) on the activity of the cGMP/cAMP
signalling cascades. The models should quantify contributions to the signalling process, coming
from different molecular activities and depending on concentrations of key components in platelets.
Within these frames we further investigated possible mechanisms for compartmentalized signalling,
relevant to understand NO/cGMP mediated cAMP/PKA activation. Signal compartmentalization
has been reported experimentally in platelets [20] and we wanted to investigate how different
compositions of the signalling components would affect the signalling response in a cyclic nucleotide
signalling compartment.
2.2. A Steady State Model of the NO-cGMP-PKG Pathway
The pre-steady state NO-induced cGMP formation has been investigated in several studies [4,21,22].
Under such conditions where NO stimulation has been lacking during in vitro platelet preparation,
a pulsed cGMP response is observed prior to relaxation to steady state levels. We here focus on the
steady state level of cGMP, as platelets are under constant exposure to NO in vivo. The activation of
soluble guanylyl cyclase (sGC) was modelled as described (Materials and Methods), relying mainly
on the quantitative measurements of sGC and cGMP-PDE activities performed on human platelets
(Table 1, [4]).
The cGMP produced can bind to the two cGMP binding sites of PKG, the GAF-domains of PDE5
and PDE2, and the active site of PDE3. The level of the PKG receptor is very high levels in human
platelets (7.3 µM) [33], giving 14.6 µM cGMP binding sites from this receptor alone. The levels of PDE2,
3 and 5 have also been reported but the high estimates found using quantitative western blotting
was not consistent with immunostaining of platelets [14] or mass spectrometric measurements [18].
The modelling performed in those studies relied on only a fraction of platelets PDEs being present
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in a catalytically competent state. We have therefore not included cGMP bound to the GAF-domains
of PDE5 or PDE2 or to the active site of PDE3 when calculating total cGMP levels. Such binding, in
particular the tight binding to the PDE5 GAF-A domain, could indeed influence the measured cGMP
level, depending on the experimental method used.
Table 1. Description of model parameters. The kinetic parameters used in the different models are
shown below. For the two compartment models, the Vmax values were varied as described in the
figures. For models where PDE phosphorylation was incorporated ([PDE5]tot 1.0 µM, [PDE3]tot 1.2 µM),
the Vmax values were refitted to experimental cNMP values. [GTP] fixed at 600 µM.
Enzymes Reactions Parameters Ref.
sGC
sGC + NO⇐⇒ sGC:NO kf = 300 µM
−1 s−1, kb = 14 s−1
K1 = kb/kf = 46.7 nM
[23]
sGC:NO⇐⇒ sGC* 1 kf = 1000 s
−1, kb = 280 s−1
K2 = kb/kf = 0.28
[23]
GTP −→ cG 3 VsGCmax 2 = 0.05, KsGCm = 100 µM [4,24]
sGC* GTP −→ cG VsGC∗max = 20, KsGC∗m = 50 µM [4]
PDE5/pPDE5 4
PDE5*⇐⇒ PDE5 + cG KPDE5D = 130 nM [7]
pPDE5*⇐⇒ pPDE5 + cG KpPDE5D = 30 nM [7]
cG −→ GMP V
PDE5
max = 39.0, KPDE5m = 4.60 µM,
KPDE5i = 0.70 µM [5,6,25]
PDE5*/pPDE5* cG −→ GMP V
PDE5∗
max = 117, KPDE5∗m = 1.00 µM,
KPDE5∗i = 0.70 µM
PDE2
PDE2*⇐⇒ PDE2 + cG KPDE2D = 2.00 µM [26]
PDE2*⇐⇒ PDE2 + cA KPDE2D = 25.0 µM [26]
cG −→ GMP VPDE2max,cG= 24.0, K
PDE2
m,cG = 120 µM [27,28]
PDE2* cG −→ GMP VPDE2∗max,cG= 240, K
PDE2∗
m,cG = 15.0 µM [27,28]
PDE2 cA 5 −→ AMP
VPDE2max,cA= 24.0, K
PDE2
m,cA = 120 µM,
KPDE2i = 120 µM
[27,28]
PDE2* cA −→ AMP
VPDE2∗max,cA= 240, K
PDE2∗
m,cA = 20.0 µM,
KPDE2∗i = 22.0 µM
[27,28]
PDE3/pPDE3 6 cA −→ AMP V
PDE3
max = 1.2, KPDE3m = 150 nM,
KPDE3i = 60.0 nM
[29]
AC −→ cA 0.93 µM−1s−1
PKG
PKG(cG)⇐⇒ PKG + cG KD = 55.0 nM [30]
PKG(cG2)⇐⇒ PKG(cG) + cG KD = 750 nM [30]
PKA
R(cA)C⇐⇒ RC + cA KD = 2.90 µM [31]
R(cA2)C⇐⇒ R(cA)C + cA KD = 2.90 µM [31]
R(cA2)C⇐⇒ R(cA2) + C KD = 1.00 µM [32]
1 Activated enzyme forms are indicated (*), 2 Vmax values are given as µMs−1, 3 cGMP abbreviated cG,
4 phosphorylated PDE5 has higher affinity for cGMP binding to the GAF A domain (KD 30 nM) and slightly
higher Vmax (1.2 fold), 5 cAMP abbreviated cA, 6 phosphorylation of PDE3 increases its maximal activity 3 fold.
The present platelet cGMP model differs from previous models [14,18,21,34] by considering
the impact of cGMP binding to cGMP receptors, like PKG, which has an unusually high expression
in platelets (7.3 µM) and has been found experimentally to protect cGMP from PDE5 mediated
degradation [30]. Such sequestration decreases the concentration of free cGMP available for
degradation by PDE5, allowing the model to reach the experimentally determined steady state
cGMP-level at conditions with higher PDE5 Vmax than in absence of sequestration. The basal platelet
cGMP level is reported to be in the low microM range (0.45 µM). This value is in the range of the
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binding constant (KD 0.75 µM) of the low affinity site in platelet PKG Iβ [30]. However, a basal cGMP
level (total conc.) at that level corresponds to a free cGMP concentration 100 fold less. This low basal
cGMP level could only be obtained with a basal GC activity that was very low (1/400 of maximal),
which is close to measurements made on the purified recombinant GC enzyme [24]. Using NO-donors,
a maximal steady state cGMP level of ~7.6 µM [16] was obtained, which we have used as maximal
total cGMP-concentration in our model (Figure 2A). This gives an NO-response curve that is sensitive
to low NO-concentrations, in concordance with physiologically realistic values (0.1–5 nM [35]). It is
worth mentioning that the half maximal response is considerable lower than that of the GC (11 nM
NO), probable due to the large buffer effect of the PKG high affinity site (Figure 2B), as half maximal
free cGMP is at NO concentrations closer to the half maximal GC activation (Figure 2C).Int. J. Mol. Sci. 2018, 19, 612 5 of 21 
 
 
Figure 2. One-compartment model of platelet NO/cGMP signalling. (A) The total concentrations of 
cGMP in platelets (bound & free) were estimated by mechanistic modelling in response to different 
NO concentrations, in the absence () or presence of dipyridamole (, 1.0 µM). The key molecules 
that determine free and bound cGMP-levels are illustrated in the reaction network. (B) shows the 
computed levels of cGMP-bound PKG Iβ at different NO concentrations in the absence (open 
symbols) and presence (closed symbols) of dipyridamole. Binding of cGMP to the high-affinity site 
(,, dotted line) and both sites (,, solid lines) are shown. (C) shows the predicted concentration 
of free cGMP at different NO concentrations in the absence () or presence of dipyridamole (). The 
inset shows predicted PKG activity at different cGMP concentrations for non-phosphorylated (solid 
line) and completely autophosphorylated PKG (pPKG, dotted line). 
2.4. PKG-Mediated PDE5 Phosphorylation Has Little Influence on the Steady State NO-cGMP Response 
Curve 
Phosphorylation is reported to affect PDE5 and 3 activities in platelets. For PDE5, 
phosphorylation seems to mainly affect binding of cGMP to the GAF-A domain, lowering the KD 
from 130 to 30 nM [7], which is expected to give a slightly steeper cGMP response curve to NO.  
We also included a 20% increased Vmax by phosphorylation but since the model is adjusted for 
experimentally determined cGMP levels, this had only minor effect on the model behaviour. For rat 
Figure 2. One-compartment model of platelet NO/cGMP signalling. (A) The total concentrations of
cGMP in platelets (bound & free) were estimated by mechanistic modelling in response to different
NO concentrations, in the abse ce (#) or presence of dipyridamole ( , 1.0 µM). The key molecules
that determin fr e and bound cGMP-levels are illustrated in the reactio network. (B) shows the
computed levels of cGMP-bound PKG Iβ at different NO concentrations in the absence (open symbols)
and presence (closed symbols) of dipyridamole. Binding of cGMP to the high-affinity site (4,N, dotted
line) and both sites (#, , solid lines) are shown. (C) shows the predicted concentration of free cGMP
at different NO concentrations in the absence (#) or presence of dipyridamole ( ). The inset shows
predicted PKG activity at different cGMP concentrations for non-phosphorylated (solid line) and
completely autophosphorylated PKG (pPKG, dotted line).
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2.3. Effects of the Moderate PDE5-Inhibitor Dipyridamole on cGMP Levels
We have previously shown that the moderate PDE5 inhibitor dipyridamole does not affect
thrombin-induced shape change in the absence of NO but prolong the NO-mediated inhibition of
platelet shape change [15]. By including dipyridamole in the model as a competitive PDE5 inhibitor
(Ki = 0.7 µM), we could test whether PDE5 inhibition alone could explain our previous experimental
observations and estimate the effect of dipyridamole at all NO levels (Figure 2A). We found that
dipyridamole (1.0 µM) increased the total cGMP level at NO stimulation by 23% (at maximal NO),
close to our experimental observations (24%).
The model was also used to estimate the effect of dipyridamole on PKG activation. Notably,
the rather low maximal cGMP-level in platelets compared to the high level of PKG gave a low maximal
activation of this kinase (19%) and a sluggish response to NO (Figure 2B). However, dipyridamole is
predicted to have a larger impact on PKG activation (>72% Figure 2B,C) than expected from the 23%
increase in total cGMP. This can be more easily understood from the dipyridamole-induced changes in
free cGMP, which were roughly doubled (Figure 2C).
2.4. PKG-Mediated PDE5 Phosphorylation Has Little Influence on the Steady State NO-cGMP Response Curve
Phosphorylation is reported to affect PDE5 and 3 activities in platelets. For PDE5, phosphorylation
seems to mainly affect binding of cGMP to the GAF-A domain, lowering the KD from 130 to 30 nM [7],
which is expected to give a slightly steeper cGMP response curve to NO. We also included a 20%
increased Vmax by phosphorylation but since the model is adjusted for experimentally determined
cGMP levels, this had only minor effect on the model behaviour. For rat platelets the phosphorylation
stoichiometry of PDE5 was found to remain unchanged during NO stimulation [34], whereas it has
been found to increase in human platelets, however not quantified [4]. We wanted to investigate
the impact of a relatively large increase in PDE5 phosphorylation, rising to 50% at maximal NO,
on the cGMP response curve (Figure 3A). In spite of having a 150 fold increase in phosphorylation,
the impact was very modest on both total cGMP- and free cGMP-levels (Figure 3B,C). This fits with
observations on the effect of PDE5 phosphorylation of human platelet cGMP response to NO [36].
As expected, dipyridamole increased the maximal PDE5 phosphorylation but this had only minor
effects on the cGMP levels compared to the model without PDE5 phosphorylation (Figure 3A–C).
Possibly, the PKG-mediated PDE5 phosphorylation is functionally implicated in the dynamics of
platelet function, rather than the steady state responses. Thus, a more than 4 fold increase in affinity
for the cGMP-activation site is expected to influence the platelet response to subsequent stimuli during
their flow in the blood stream.
2.5. Modelling the Influence of cGMP on Platelet cAMP Levels through PDE3
Nitric oxide does not activate platelet adenylate cyclase (AC). Furthermore, inhibitors of PDE3
but not of PDE2, can mimic the inhibitory effect of NO on platelet shape change [8]. We therefore
first studied the activity of PDE3 in response to cGMP and cAMP. PDE3 is competitively inhibited by
cGMP, effectively shifting its half maximal activation by cAMP (Figure S1A). As the AC activity is
constant in NO stimulation and at different cAMP concentrations, the steady state level of free cAMP
as a function of a given AC activity (basal: VACbasal) or stimulated: VACstim) and PDE3 activity (VPDE3)
for different cGMP concentrations, is given by the cAMP concentrations where the two activities are
equal (Figure S1A, blue or red circles).
Increasing cAMP levels will bind to and activate platelet PKAs. The PKA isoform or isotype
composition of platelets is not completely resolved. We therefore applied kinetic data from both human
regulatory subunit Iα and IIα with purified bovine heart catalytic subunit (C) (Table 1, [31,32]). As the
tetrameric PKA holoenzyme is symmetric, we modelled it as a heterodimer of a regulatory subunit (R)
and catalytic subunit (C). The activation of PKA was modelled by sequential binding of two cAMP
ligands to the R-subunit, with subsequent dissociation of the cAMP-bound holoenzyme complex
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as shown (Table 1, Figure S1B). The modelled response is for PKA at the level reported in platelets
(3.1 µM) giving a maximal of almost 1.2 µM (39%) free C-subunit at saturating cAMP concentrations.
For the cAMP pathway, considerable amounts of PKA-bound cAMP were predicted, i.e., for 10 µM
free cAMP, total platelet cAMP of almost 16 µM was predicted, with about 1 µM free PKA catalytic
subunit levels (Figure S1B).
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Figure 3. Effect of PKG mediated phosphorylation of PDE5 on cGMP response to NO. Assuming
a maximal 50% phosphorylation of PDE5 in maximally NO stimulated platelets, we calculated the
impact of this phosphorylation by PKG on the NO-stimulated cGMP response curve. (A) shows
the phosphorylation stoichiometry of PDE5 at different concentrations of NO in the absence (#) or
presence ( ) of dipyridamole (1 µM). In (B,C) we compare the model with (in red) and without (in black)
phosphorylation of PDE5 included and the impact on total platelet cGMP levels (B) or concentration
of free cGMP (C). The model without PDE5 phosphorylation is shown in black, pPDE5-model in red.
Open and closed symbols denote absence and presence of dipyridamole, respectively. For both models,
the Vmax of PDE5 was fitted to the same maximal and basal levels of total cGMP.
Phosphorylation and activation of PDE3 by PKA is a well-known mechanism for
feedback-inhibition. For illustrations, the effect of an assumed PKA-mediated PDE3 phosphorylation
of maximal 90% was modelled (Figure S1C) with the concurrent alterations in the PDE3 activity
(Figure S1D). Such a strong feedback regulation gave a clear reduction of the cAMP steady state
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response to increased cGMP levels, but affected the steady state cAMP level in response to increased
AC activation more. Thus, the cAMP increase upon cGMP stimulation (to 200 nM) now became similar
to that obtained by a 5-fold increase in AC activity (Figure S1D, circles 1 and 2, red versus black).
2.6. Modelling Global Platelet cGMP to cAMP Cross-Talk
It is well known that platelet PDE2 contributes extensively to the control of cAMP levels [37].
The PDE2 kinetics is complex due to its dual specificity in the catalytic domain and that both cGMP and
cAMP can bind to its GAF domain and activate the enzyme. Multiple binding reactions to activating
GAF domain and Michaelis Menten equations were used to describe the behaviour of this enzyme in
concordance with experimental observations. This also gave a better fit to experimental data on PDE2
purified from human platelets than existing models (Table 1, Figure S2).
To model the cAMP response to different NO concentrations the model was expanded to include
AC as well as PDE2 and PDE3. A constant basal AC activity (<1 µM−1 s−1 [38]) was set to balance
the cAMP-PDE activity at the cAMP concentration found experimentally. Similarly as for cGMP,
cAMP association to PKA was included here as described (Figure S1). Others and we have previously
reported very modest total cAMP changes upon NO stimulation of platelets [15,16]. This was used
to fit the relative levels of PDE2 and 3 activities (Figure 4A) and our model accurately predicted the
measurable changes in the NO-cAMP response by dipyridamole (1.0 µM).
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and adjusting the enzyme activities to reach experimentally observed cAMP levels at basal and NO
stimulated conditions. (A) the predicted cha e i 2- (4N), PDE3- (#, ) and total cAMP-PDE-
(,) activity was estimated in response to NO in absence (open) and prese ce (closed) of dipyridamole.
In (B) we sh w the cAMP-resp nse to NO for total cAMP (solid line without dipyridamol , dotted
line with dip), free cAMP (#, ) an active PK (,). Open and closed symbols denote absen e or
presence of dipyridamol (1.0 µM), r spectively.
Int. J. Mol. Sci. 2018, 19, 612 9 of 21
PDE3 and PDE2 have different sensitivities towards cGMP and very different kinetic
characteristics. It was therefore surprising that similar cAMP levels between none and high NO levels
led to very small alterations in NO-mediated cAMP responses across the whole range (Figure 4A).
Thus, the activities of PDE2 (cGMP-stimulated PDE) and PDE3 (cGMP-inhibited PDE) are balanced
throughout the range of NO concentrations and in the presence of both NO and dipyridamole.
Evidently, the total cAMP-PDE activity was unresponsive to both cGMP and dipyridamole. This model
could therefore not explain the mechanism behind NO-mediated PKA activation. However, such a
global model is a good starting point for investigating NO-mediated PKA activation in signal
compartments where the distribution of signalling proteins could vary.
2.7. Two-Compartment Modelling of cGMP/cAMP Crosstalk through PDE3
The lack of cAMP response to NO in the global cNMP-model and the mimicking of NO effect by
PDE3 inhibition could suggest that shape change is governed by events in a rather small compartment
enriched in PDE3 and poorer in PDE2. As a first approach, we investigated the cAMP response
in a diffusion-coupled compartment containing AC, PDE3 and PKA (Figure 5A). Clamping of the
external free cAMP (at the level found in our homogeneous, one-compartment model) and internal
free cGMP enabled us to investigate the optimal conditions for PKA activation (Figure 5). It is
clearly seen that a cAMP-responsive compartment is feasible at different levels of internal AC
activity (Figure 5B–D), as the basal cAMP-level can be kept low at sufficiently high PDE3 levels.
However, lower compartment AC activities limit the maximal cAMP level that can be obtained in the
presence of diffusion. We also included a situation where a PDE3 compartment is exposed to higher
external cAMP levels (e.g., arising from inhibition of PDE2) but at the same diffusion rate constant
(Figure 5E). This illustrates several issues; the resistance of the compartment against cAMP overflow at
different PDE3 levels, the potential for synergistic communication between two compartments and the
possibility of having cAMP-responsive compartments even in absence of AC-activity, given that the
basal cAMP-level of the external compartment is relatively high.
2.8. A Modest Redistribution of Platelet PDEs Suffice to Generate NO Mediated PKA Activation
Having established the signalling capacity for a compartment with negligible levels of PDE2,
we moved to more realistic models. In particular, since both PDE2 and 3 are considered to be mainly
soluble in platelets, even though membrane-bound isoforms and binding partners are known for
both PDE isotypes [39–43]. Platelet shape change involves cytoskeletal rearrangements close to the
circumferential microtubule band where also the dense tubular system (DTS) of platelets is located.
Interestingly, the DTS is rich in platelet AC activity [44]. Based on these experimental findings we
constructed a two-compartment model where a postulated small shape change signalling compartment
(SCComp, 10% of the platelet volume) had elevated concentration of AC (2 fold, Figure 6). Further,
we generated sets of models where the distribution of PDEs between the compartments were different
but while keeping other protein species the same and the total PDE activity such as to agree with
experimental measurements of total cyclic nucleotide levels.
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Figure 5. The kinetic properties of PDE3 facilitates cAMP-compartment signalling in absence of AC
activation. (A) We investigated the formation of a steady state difference in cAMP concentration
between a small compartment that were diffusion coupled to an external large compartment, that was
clamped at a fixed cAMP concentration ([cAMP]Ex). The levels of PDE3, cGMP concentration and AC
activity were varied to see how this affected the steady state concentration of free cAMP in the small
compartment, in the presence of diffusion. The AC activity was kept constant (B–E) in each case and
the external cAMP concentration was clamped at 0.4 µM (B–D), which is similar to the free cAMP
concentration obtained in the homogeneous, one-compartment model (Figure 4). The Vmax of PDE3
and the concentr tion of cGMP (repres ting NO) were varied and for each pair of values, a ste dy
state cAMP concentration (in compartment) was calculated from the opposing activities of PDE3 and
AC (fixed). The Vmax value for PDE3 (1.2 µM−1 s−1) in the one-compartment model is shown as dotted
line (C). In (B–D) the AC activity in the compartment was set to 0.5×, 1.0× and 2× of that used in
the one-compartment model (Figure 4, 0.93 µM−1 s−1), respectively. (E) shows the case of elevated
external cAMP, e.g., as has been reported by inhibition of PDE2, where the compartment AC activity is
set to zero.
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Figure 6. Modelling the effect of PDE redistribution on the PKA response to NO. Starting from
the one-compartment model, we investigated how distribution of PDEs influenced cAMP and
PKA-activation in a two-compartment model (see supplemental text for details), where a PDE3-rich
PKA/VASP compartment (vcomp = 0.1 × vtot = 0.52 fl) was spatially separated from the remaining
platelet intracellular volume (vcyt 90% of total). The compartment AC concentration was assumed to be
two fold that of the one-compartment model (Figure 4, see Results). The level of PDE3 and PDE2 in the
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compartment was set to n and 1/m fold that of the one-compartment model (Table 1), respectively,
keeping the total platelet PDE2, 3 and AC activities as to fulfil experimental cyclic nucleotide
measurements. (A–I) show the PKA response (relative to basal) at different NO concentrations.
For (A–C) the shape change regulating compartment (SCComp) response in absence (#) or presence
( ) of dipyridamole (1.0 µM) and the bulk cytosolic (external compartment) response (solid line, dotted
line in presence of dipyridamole) was calculated at a steady PDE3 level, varying the PDE2 activity
(1×, (A); 0.5×, (B); 0.25×, (C), Table 1). (D–F) shows the calculated compartment PKA activation in
colour code (scale from 0.5 to 6.5 fold activation; (PKA activity at 1 µM NO)/(PKA activity at 0.01 nM
NO)), for different distribution of PDE3 and 2. In (D) the compartment PDE5 level was set to 0.5 fold
the average, whereas in (E,F) it is set to 1- and 2 fold, respectively. In (E), the models that give rise to
the compartment PKA activation curve (#) in (A) to (C) are marked (white dotted circles). (G–I) shows
the same heat diagrams but scaled between their minimal and maximal fold PKA activation. (J) shows
the compartment PKA response range, at different compartment-levels of PDE5, in the absence (white)
or presence (black) of dipyridamole (1.0 µM). The PKA response is shown as the difference between
maximal and basal relative to basal (100%). For comparison, we show the steady state levels of Ser157
phosphorylated VASP during NO stimulation in the absence and presence of dipyridamole. (K) shows
the compartment PKA-activity at basal conditions (white) and during total inhibition of PDE2 (black).
For comparison, we show the compartment PKA response to 5 nM NO (grey).
A modest three-fold increase in PDE3 activity in the SCComp relative to average was enough to
facilitate a cAMP-response to NO and this was further increased by a 3-fold decrease in PDE2 level.
This was more evident by increasing the compartment PDE3 level to 4-fold (Figure 6A–C), where the
effect of reducing PDE2 level on the PKA response is also illustrated. The gain in PKA response was
increased most going from 1.0× to 0.5× PDE2 in the SCComp, whereas the dipyridamole response
was increased more upon further reduction in PDE2 (Figure 6A–C). The model predicted that while
NO/dipyridamole enhanced the PKA activity strongly in the small compartment, the PKA activity
decreased in the bulk cytosol. Increased phosphorylation of VASP at the Ser157 PKA site, which
blocks nucleation of actin polymerization [45], would therefore be likely to occur in the vicinity of
the SCComp.
As PKA can activate PDE3 though phosphorylation, we tested how this could influence the
responsiveness of the SCComp. Although we do not know the extent (stoichiometry) of PDE3
phosphorylation upon NO stimulation we estimated an expected extent of PDE3 phosphorylation
based on measurements of PDE3 activation and phosphorylation at different cAMP stimuli in platelets.
The corresponding expected effect of PDE3 activation based on the PKA activation in the SCComp
in response to NO was then included (Figure S3). At the conditions modelled here, it seems that
feedback inhibition via PKA phosphorylation of PDE3 was not an important regulatory feature
(see supplemental text for more discussion).
Since PDE5 is reported to be partially located in the ER membrane [20], we also investigated the
impact of PDE5 concentration on the compartment PKA response (Figure 6 D–I). Here we show the
maximal PKA response relative to basal (fold activation; [Csub.] at 1 µM NO/[Csub.] 0.01 nM NO) for
a range of models where the PDE distribution between SCComp and the rest of the platelet was varied.
Again, for each model the total platelet PDE activities were kept constant. Thus, for three model
sets the PDE5-activity of the SCComp was varied to 0.5×, 1× and 2× that of the one compartment
model. For each, an array of PKA response values were calculated for different models of PDE3
(1–10×) and PDE2 (1.0–0.1×) SCComp levels compared to the average one-compartment model.
Clearly, the compartment activity of PDE5 is an important determinant for the PKA responsiveness at
conditions where the PDE3 activity exceeds that of PDE2. Going from 0.5 to 2 fold in compartment
PDE5 activity had a large impact on the PKA activation response to NO, which could explain why
PDE5 inhibitors have such an effect on NO-inhibited shape change.
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We have previously measured the VASP phosphorylation response on the Ser157 PKA-site in
the presence and absence of dipyridamole [15]. The fold change observed there could suggest that
the PDE5 level in the SCComp was slightly higher than the overall activity (1.5–2×) (Figure 6J).
However, this can only be taken as suggestive evidence, as we do not know the abundance of VASP
in the predicted SCComp relative to that of entire platelet. We further investigated the SCComp
PKA response to total inhibition of PDE2 (Figure 6K), as the latter is known to have little impact on
inhibition of platelet shape change experimentally [8]. A modest PKA response was observed to PDE2
inhibition, as compared to a moderate NO stimulation.
3. Discussion
Imbalanced cGMP or cAMP signalling causes several diseases of the cardiovascular system.
Lowered cAMP signalling in platelets and leukocytes, e.g., due to endothelial dysfunction, is associated
with risk of thrombosis and atherosclerosis and in endothelial cells themselves, cAMP is an important
regulator of vascular permeability [11]. Cross talk between cGMP and cAMP is functionally implicated
in several cell types other than thrombocytes, e.g., beta-adrenergic signalling in cardiomyocytes
(for review, see Zaccolo and Movesian [9]) and smooth muscle relaxation [10]. In cardiac myocytes
as in platelets, the impact of cGMP on cAMP degradation through PDE2 and 3 can give rise to
both inhibitory and cooperative cross-communication of these second messenger systems [46,47].
This makes it particularly interesting to investigate the nature of this signalling communication, also in
the perspective of pharmacological targeting and the possibility of off-target effects.
VASP Ser157 phosphorylation is a much used experimental readout for PKA activation.
The importance of VASP in platelet NO signalling was clarified in a convincing study by Gawaz
and co-authors [48]. Using in vivo microscopy of platelet adhesion to carotid arteries they showed
that platelets from VASP knockout mice were unresponsive to NO also in wt recipients. Earlier studies
have shown that VASP is important for mediating some of the inhibitory effects of cGMP and cAMP on
platelet aggregation, but VASP-deficiency does not affect calcium signalling or secretion [49]. The exact
mechanism of VASP action in cells is not fully understood.
Platelet shape change is known to involve reorganization of the circumferential microtubule band,
which is important for maintaining the discoid shape of thrombocytes. The dense tubular system (DTS),
the residual platelet endoplasmatic reticulum (ER), is associated with the circumferential microtubule
band (for review, see White [50]). In addition, the actin cytoskeleton is important for driving extension
of pseudopodia and VASP supports the extension of F-actin [51]. It therefore seems reasonable that
the relevant signalling compartment is located in the vicinity of the actin and microtubule cortex in
association with the DTS. In this region, higher cAMP production can be expected as well as spatial
restrictions on the diffusion of the cyclic nucleotides. However, this has to our knowledge not been
measured in platelets.
It has remained controversial how moderate changes in cAMP associated with NO stimulation
could activate PKA sufficiently. Especially, in light of recent findings on the dissociation of the
cAMP-saturated PKA holoenzyme, only moderate activation can be expected and was also found
in the modelling (maximal activation of 39% compared to total PKA) even at saturating cAMP [32],
due to high levels of PKA in platelets [33]. This has been taken into account in the model presented
here. Since it is unlikely that VASP exists at saturating concentrations for both kinase and phosphatase
(which could give rise to zero order ultrasensitivity), other mechanisms must come into play [52].
Others and we have pointed to the importance of PDE3A in mediating NO responses in platelets [8,13].
In our model, we make no assumption about the nature of our signalling compartment except for PDE3
activity, which should be present in excess over PDE2 activity, as compared to the remaining platelet
volume. In earlier studies of platelet PDE isolation and characterization it was considered that the
platelet isotypes were mainly soluble [37]. However, reports that are more recent suggest that this may
be an oversimplification, at least for PDE5 [20]. Several isoforms of PDE2 and 3 are known to associate
both strongly and dynamically with membranes [42,43]. In addition, protein-protein interaction has
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been reported for both PDEs [39,41] but is so far not found in association with A-kinase anchoring
proteins, which often sequester PDE4 [53]. Thus, a dynamic interaction with membranes for both
PDE2 and 3 is possible but is yet to be firmly established in platelets. Interestingly, in cardiac myocytes,
membrane associated isoforms of PDE2A and 3A are found in both the plasma membrane and ER,
respectively [40,54]. Furthermore, photoaffinity labelling of platelets with [32P]-cGMP show evidence
for membrane located PDE3A [55]. The low affinity of PDE2 for cGMP and cAMP makes it unsuitable
for comparable experiments. In platelets, PDE3A has been found located with the leptin receptor in a
signalling complex where AKT activation of PDE3A is postulated to participate in the leptin-induced
platelet activation [56].
An interesting finding by the modelling was the influence of PDE5 on PKA activation. Thus,
low levels of PDE5 activity enables a larger PKA response to similar NO stimuli. This was intriguing
as PDE5 is partially located to the ER membrane, although with a lower specific activity than unbound
PDE5 [20]. Studies that quantify PDEs and other cNMP signalling components consistently in platelets
would provide highly valuable information for model generation [14,18]. The existing uncertainties
make it difficult to conclude on the nature and composition of signalling compartments in platelets as
well as in other cells.
The PDE5 inhibitor dipyridamole is favourable in combination with low doses of acetylsalicylic
acid (aspirin) as dual antiplatelet therapy for secondary prevention of ischemic stroke [17]. However,
dual antiplatelet therapy is not used over extended periods due to high bleeding risk. An alternative
strategy may be to potentiate endothelial function. Inhibiting the rate-limiting enzyme in cholesterol
biosynthesis (3-hydroxy-3-methylglutaryl-CoA reductase) with statins is found to increase the
production of NO in an eNOS-dependent manner [57]. Moreover, additive NO-dependent protective
effects of statin and dipyridamole on blood flow and stroke have been reported [58]. Thus, treatment
with statins, which increase endothelium-derived NO production and subsequent platelet cGMP
production, in combination with PDE5 inhibition by dipyridamole may have a preventative effect on
cardiovascular disease without increased risk for bleeding.
A second observation in the models, that does not involve cNMP cross-talk, was the sluggish
activation of PKG in platelets, due to sequestration of cGMP at the high affinity site of PKG Iβ and low
occupancy of the low affinity site even at saturating NO concentrations. This observation suggests
that selective agonists of the low affinity site of PKG Iβ would greatly improve the activation status
of PKG in platelets. This could be a targeting option worth testing as an alternative strategy for
antiplatelet therapy.
Surprisingly, not much has been done on quantitative modelling of cGMP-cAMP cross talk. To our
knowledge this is the first compartment model of cyclic nucleotide signalling in platelets and the first
study to investigate the impact of AC and PDE2/PDE3/PDE5 compartmentalization on PKA activation
through NO signalling. A similar modelling approach was used to investigate PDE interactions in
cardiac β-adrenergic signalling [59]. We believe that this work and similar modelling approaches
provide important contributions to the quantitative understanding of cyclic nucleotide signalling and
in particular the signalling communication between these second messengers. This is important as the
pathways regulate crucial functions in many cell types and tissues. A quantitative understanding of
the behaviour of these pathways and their interactions is needed to understand key characteristics that
are important for their function. Furthermore, by interrogating such models from different cell types,
improved strategies to target cNMP signalling more selectively can be identified, that has minimal
off-target effects in other cells or tissues.
4. Materials and Methods
4.1. Signalling Pathway and Literature Quantitative Information
The active components of the NO-cGMP and cAMP signalling pathways in platelets are well
known (Figure 1). In addition, the kinetic characteristics and quantitative information about the
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network components are reasonably well described (Table 1). All PDE enzymes were modelled with
Michaelis Menten kinetics for each of their activity states. Thus, both PDE5 and 2 are activated by
binding of cGMP to their GAF domains. PDE2 is also activated by binding of cAMP as well, albeit
with a higher dissociation constant. The KD values for activation of PDE5 and 2 (Table 1) determine
the relative abundance of non-activated and activated enzyme (denoted by * in Table 1) at different
concentrations of cGMP and cAMP. We have used different kinetic properties in the activated and
non-activated PDEs as for sGC (Table 1). Competitive kinetics was included for all PDEs (Table S1);
for PDE2*, cGMP inhibits cAMP degradation (Ki = 22 µM for the activated enzyme); for PDE3, cGMP
strongly inhibits cAMP degradation; for PDE5, dipyridamole inhibits cGMP degradation of activated
and non-activated enzyme states with the same Ki. The kinetics of PDE2 is described by several
Michealis Menten equations to include as much as possible of the kinetic properties reported for
this enzyme. Temperature dependency and sensitivity toward type of divalent ion in the assay are
important to consider when comparing in vivo and in vitro data. We used the kinetic properties at
physiological conditions as reference for our model. The transition between low- and high- activity
states, with increased substrate affinities, was used to capture the cooperativity of PDE2. The model
showed similar kinetic properties as reported (S0.5(cAMP) = 50 µM, Hill 1.3; S0.5(cGMP) = 35 µM,
Hill 1.1) including a bi-phasic cGMP stimulated cAMP degradation, peaking at about 7 µM cGMP
as observed for human platelet PDE2 (Figure S2). For comparison, we included the behaviour of
published PDE2 models at similar conditions. Thus, the study of Wangorsch et al. was focused on
cAMP signalling and therefore did not include cGMP-modulation of PDE2, as it was not within the
scope of the model [14]. For the more recent modelling of heart cAMP and cGMP signalling a PDE2
modelling approach similar to ours was applied [59]. However, for the conditions reported in platelets
it did not seem to fit well (Figure S2).
For PKA, the binding affinity of cAMP to the A- and B-site of the holoenzyme is not described.
We therefore assumed the affinity for each of the two steps (macroscopic description of binding, i.e.,
not considering separate binding to the A- or B-site) to be similar, which gives an overall cAMP-binding
curve that is in agreement with recently described cAMP-binding to the type-I holoenzyme [31].
The dissociation constant for activation of the cAMP-saturated PKA holoenzyme was set to 1 µM,
which is similar to that reported for type II (intermediated between MgATP-and MgADP-bound
C-subunit) and for type I at moderate substrate concentrations [32].
4.2. Modelling Approach
We have applied a mechanistic modelling approach relying on experimental-based mechanistic
and kinetic description of platelet signalling using ordinary differential equations. This is a common
approach and has been used in several previous studies on platelets [14,18,19] and assumes well-mixed
compartments. Although, platelets have small volumes (5–6 fl), the proteins involved are present at
very high levels and it should therefore be valid to not use stochastic differential equations. The proteins
involved in the signalling pathways are well described, including the equilibrium binding affinities
and the enzyme kinetic constants (Table 1), however, many of the rate constants are not well elucidated.
We have therefore mainly focused on the steady state behaviour of the model. The modelling
activity was used to quantify contributions to the signalling process coming from different molecular
mechanisms at conditions that agree with reported platelet activities and concentrations. Within these
frames we further investigated possible mechanisms for compartmentalized signalling, relevant to
understand nitric oxide/cGMP mediated cAMP/PKA activation.
The total platelet cyclic nucleotide concentrations were calculated as described (Equations (1)–(6)),
taking into account binding of cGMP and cAMP to their respective kinases, as these are present
at high concentrations (below). Ordinary differential equations were used to describe changes in
cGMP/cAMP (cG/cA) levels (Equations (7)–(10)) as the system evolved to its steady state. Importantly,
this does not necessarily mean that the model correctly describes the temporal changes in platelets
but it will describe the steady state levels of cNMP and the kinase activities. For the homogeneous
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one-compartment model (Figure 4), diffusion-mediated transport was ignored. Based on a total
platelet volume of 5.2 fl, we assumed an external compartment (4.68 fl) and shape change regulating
compartment (SCComp, 0.52 fl) comprising 10% of the total volume [33].
The total level of PKG, 7.30 µM (monomer) and PKA, 3.10 µM (modelled as a dimer of Regulatory
and Catalytic subunit, RC), as reported [33]. Binding of cyclic nucleotides to their downstream
kinases are denoted by PKG(cGn) and R(cAn)C for the cGMP- and cAMP-dependent protein kinases,
respectively (n = 1, 2). Binding of cGMP to PKG-Iβ was modelled as sequential binding of cGMP,
first to the high affinity site, second to the low affinity site, due to a 14 fold difference in affinity
between the sites. Modelling PKG and PKA as monomers and dimers, respectively, is valid as no
interchain interaction is reported for the dimeric PKG and regulatory PKA subunits [60,61].
The kinetics of NO dependent cGMP metabolism in platelets is has been investigated in several
studies in rats [4,21,34]. During the first 10 seconds after NO stimulation, a pulsed increase in
cGMP is observed before settling at a steady state concentration much lower than the maximal
peak concentration (e.g., peak at 300 pmol cGMP/mg protein at 50 nM NO, corresponding to 150 µM
cGMP; steady state level <25 pmol/mg) [21]. This pulsed cGMP response is also found in human
platelets [4]. The activation of soluble guanylyl cyclase (sGC) was modelled as described, ignoring the
time dependent changes, as we were interested in steady state levels [34].
We used the same compartment modelling approach as described previously for cAMP
signalling [62,63] and for other signalling pathways [64], where diffusion of free cAMP and cGMP
between the compartments is proportional to the concentration difference between them (distribution
of proteins and metabolites assumed homogeneous within each compartment). Karpen and co-authors
have estimated the exchange flux of cAMP between a membranous compartment and the cytoplasm
in HEK 293 cells using a cAMP-responsive ion channel for measuring cAMP concentrations.
They reported an exchange rate of 0.8 fl/s, consistent with a diffusion rate of 3 × 10−6 cm/s (measured
diffusion rate of cAMP in cytoplasm), a barrier length of 1 µm and a cross sectional area of 0.3 µm2.
Compared to a 40 µm2 area expected for their compartment (cubic, 40 fl), we have been much less
restrictive in our estimates of barrier length (0.1 µm) and cross sectional area (0.65 µm2). However,
the diffusion rate of cAMP (3 × 10−6 cm2/s) can be expected to be reduced in platelets, due to very
high levels of cAMP binding sites (at least 6.2 µM [33]). In its bound state, cAMP diffusion would be
dramatically decreased or even absent (if PKA is anchored). Similar arguments would hold for cGMP
and for simplicity we have set the diffusion flux equal for the two nucleotides.
Assuming a similar apparent diffusion between the compartment and cytoplasm, we calculated
a plausible flux (JDiff) to be 0.44 fl/s (assuming cubic geometry [64,65] 0.52 fl compartment volume,
barrier thickness of 0.1 µm), based on 0.8 fl/s for a 40 fl compartment in HEK293 cells (barrier thickness
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where the superscript refers to the compartment (comp—shape change regulated compartment
(SCComp), cyt—external compartment) and subscript to the specific enzyme for rates and state
(bound or unbound/free) for metabolites. For PDE2, which has two substrates, this is also specified
in the subscript. Reaction rates are specified with V, volumes with υ and the diffusion flux with
JDiff. Equation (11) describes the steady state relationship between the ratio of dephosphorylation
and phosphorylation rate constants as a function of the concentration of active kinase ([Kinase*])
and the observed phosphorylation stoichiometry of PDE (SpPDE). Thus, rates of phosphorylation
(Vphos = kphos[PDE][Kinase*]) and dephosphorylation (Vdephos = kdephos[pPDE]) are represented by
linear kinetics (assuming high Km values).
4.3. Parameter Estimation
In this study, we have mainly relied on the quantitative measurements of sGC and cGMP-PDE
activities performed on human platelets [4]. Here maximal peak cGMP concentrations of about 60 µM
and maximal steady state values below 10 µM were observed (in absence of PDE inhibitors). Also here,
steady state was established well within one minute, which is typically used here. The Vmax for sGC
was set to 20 µM/s as measured in human platelets [4], whereas the basal sGC activity (kcat) was fitted
to about 1/400 of the value for the activated enzyme, which is similar to findings on the recombinant
enzyme [24]. Adjustments of the PDE Vmax activities were performed to fit measured cAMP and cGMP
levels [16], keeping total cAMP PDE activity close to 2 µM s−1 as reported at 1 µM substrate [66] and
AC activity < 1 µM s−1. A constant adenylate cyclase (AC) activity was assumed. The fitting was also
restricted by PDE2 activity being less than 10% of the PDE5 activity at 1 µM cGMP [66].
4.4. Simulations
The model was implemented in COPASI 4.11 (build 65, www.copasi.org), which uses an LSODA
ODE-solver for stiff and non-stiff systems [67,68]. The absolute tolerance was set to 1.0 × 10−12.
The models will be deposited in the biomodels.org repository.
5. Conclusions
We have performed an analysis of cGMP to cAMP cross-talk in platelets using a mechanistic
modelling approach. The modelling showed the importance of including cNMP binding to intracellular
receptors to correctly balance the activities of cyclases and phosphodiesterases and to assess the
potency of competitive pharmacological inhibitors. This is particularly evident in platelets, which
contain extreme levels of such sequestering receptors. Compartment models with heterogeneous
distribution of phosphodiesterases could account for experimental observations on NO mediated
PKA activation. The compartment models revealed an interesting relationship between the different
phosphodiesterases in platelets, which may be linked to the observed clinical efficiency of PDE
inhibitors. Further experimental evidence is required to identify the nature and composition of
signalling compartments in platelets. This is likely to provide valuable knowledge for the development
of novel antiplatelet therapies.
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